Coastal Genomics sells a proprietary technology that enables the scalable automation of a process known as gel size selection of DNA. This protocol is increasingly recognized as a means to drop costs and increase sensitivity for clinical liquid biopsy applications. Through sale of instruments and associated reagents, we will save the US prenatal testing market $3M annually, and the coming US cancer detection market $3B annually.